DDInter1524 DDInter1376
A derivative of procaine with less CNS action.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Procainamide {u} (Compound) resembles {v} (Compound) Aminohippurate
Procainamide {u} (Compound) resembles {v} (Compound) Procaine
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Procainamide {u} (Compound) binds {v} (Gene) SCN11A
Procainamide {u} (Compound) causes {v} (Side Effect) Vomiting
Procainamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alosetron
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Procainamide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Procainamide (Compound) resembles Aminohippurate (Compound)
Procainamide (Compound) resembles Procaine (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Procainamide (Compound) binds SCN11A (Gene)
Procainamide (Compound) causes Vomiting (Side Effect)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Alosetron
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Procainamide may lead to a major life threatening interaction when taken with Cladribine
Procainamide may lead to a major life threatening interaction when taken with Ivosidenib
Procainamide (Compound) resembles Lidocaine (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine